Major International Neuroscience Facility Closes, Focus Shifts to Research in Genetics

Printer-friendly versionPrinter-friendly version
Scientific Council Member Husseini Manji, MD
Husseini Manji, MD

Scientific Council Member Husseini Manji, MD, was quoted in Nature Magazine on the closing of a brain research facility of Novartis, an international pharmaceutical company. The facility aimed to discover new drug treatments for brain and behavior disorders.

Many other major pharmaceutical companies have recently closed their doors at similar research facilities, as the drug development for mental illness has become a financially high-risk effort. Despite the severe and growing need for new treatment options, many companies have pulled back on research in psychiatric disorders. A few, like Novartis, are not abandoning neuroscience, but are shifting the focus to the study of genetics in the hope of better understanding the biology of the brain to identify new treatment strategies. Dr. Manji,  underscoring the importance of neuroscience in successfully treating mental illness, stated that “things are cyclical — for those who stay the course, the breakthroughs will finally come”.

Read More

Article comments

Thank you Dr. Manji for your optimistic view of the future. Keep up the good work.

Add new comment

comments

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Please note that researchers cannot give specific recommendations or advice about treatment; diagnosis and treatment are complex and highly individualized processes that require comprehensive face-to- face assessment. Please visit our "Ask an Expert" section to see a list of Q & A with NARSAD Grantees.
By submitting this form, you accept the Mollom privacy policy.